1-20 of 221 results for subject:"Generic prescribing"
Librarians' tools
- Search time
- 0.297 seconds
- Solr query time
- 0.004 seconds
- Search query
- subject:"Generic prescribing"
- We searched for
- subject_t:"Generic prescribing" OR subject_ses:91414
Type
House
Session
More
Year
Department
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the potential impact of conflict in the Middle East on the supply of generic medicines to the UK.
To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the potential impact of conflict in the Middle East on the supply of generic medicines to the UK.
The Department is closely monitoring the Middle East conflict to assess any potential impact on United Kingdom medical supply chains through disruptions to manufacturing and logistics.
There have been limited impacts on generic medicines and the wider medical supply chain to date. We have limited direct exposure to the Middle East for medical products, and maintain well-established contingency arrangements to manage supply disruptions where these occur. These can include coordination of mutual aid, work to identify alternative products, alternative clinical practices, regulatory easements, and/or use of the Express Freight Service which can provide bespoke global logistics services in the event of critical supply disruption.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help increase the uptake of generic and biosimilar medicines to meet the objectives set out in the Government’s Life Sciences Sector Plan.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help increase the uptake of generic and biosimilar medicines to meet the objectives set out in the Government’s Life Sciences Sector Plan.
The United Kingdom is a global leader in adopting biosimilar and generic medicines, which deliver major National Health Service savings and expand patient access to effective treatments sooner.
We are working with the Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence (NICE), and NHS England to understand forthcoming biosimilars and to ensure they reach the frontline efficiently. Through NHS England’s Best Value Biologicals Framework, clinicians start patients on the most cost‑effective biologics where appropriate, and switches are made swiftly and safely. This has already delivered £1.2 billion in savings over the past three years.
As set out in the 10‑Year Health Plan and Life Sciences Sector Plan, we are streamlining regulation, improving procurement, and reducing variation in uptake. NICE’s whole‑lifecycle approach ensures clinical pathways are regularly reviewed so that patients benefit as soon as cost‑effective generics and biosimilars become available, as seen in recent cancer treatments. These actions support timely access to effective off‑patent medicines and a sustainable, competitive market for the NHS.
To ask the Secretary of State for Health and Social Care, when the Government plans to establish a task and finish group to oversee delivery of the Life Sciences Sector Plan as it relates to generic and biosimilar medicines.
To ask the Secretary of State for Health and Social Care, when the Government plans to establish a task and finish group to oversee delivery of the Life Sciences Sector Plan as it relates to generic and biosimilar medicines.
The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. As set out in the Life Sciences Sector Plan, which we developed while working closely with the sector, there is an opportunity for the National Health Service to save £1 billion over five years through biosimilars uptake, delivering value for patients and the NHS. The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.
Medicines UK and its members are represented on the Single National Formulary Industry Task and Finish Group. In addition, the Government is working to convene further task and finish groups to drive forward defined areas of the Life Sciences Sector Plan, including in the generic and biosimilars space. These groups will direct focused ministerial and official attention toward a clear set of priorities and will work closely with industry to deliver tangible progress within a set timeframe.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of reinstating the Life Sciences Council with representation from the generic and biosimilar medicines industry.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of reinstating the Life Sciences Council with representation from the generic and biosimilar medicines industry.
The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. As set out in the Life Sciences Sector Plan, which we developed while working closely with the sector, there is an opportunity for the National Health Service to save £1 billion over five years through biosimilars uptake, delivering value for patients and the NHS. The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.
Medicines UK and its members are represented on the Single National Formulary Industry Task and Finish Group. In addition, the Government is working to convene further task and finish groups to drive forward defined areas of the Life Sciences Sector Plan, including in the generic and biosimilars space. These groups will direct focused ministerial and official attention toward a clear set of priorities and will work closely with industry to deliver tangible progress within a set timeframe.
To ask the Secretary of State for Health and Social Care, what consideration has been given to the role of the generic and biosimilar medicines sector in shaping life sciences policy, in the context of it supplying around 85% of NHS prescription drugs by volume.
To ask the Secretary of State for Health and Social Care, what consideration has been given to the role of the generic and biosimilar medicines sector in shaping life sciences policy, in the context of it supplying around 85% of NHS prescription drugs by volume.
The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. As set out in the Life Sciences Sector Plan, which we developed while working closely with the sector, there is an opportunity for the National Health Service to save £1 billion over five years through biosimilars uptake, delivering value for patients and the NHS. The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.
Medicines UK and its members are represented on the Single National Formulary Industry Task and Finish Group. In addition, the Government is working to convene further task and finish groups to drive forward defined areas of the Life Sciences Sector Plan, including in the generic and biosimilars space. These groups will direct focused ministerial and official attention toward a clear set of priorities and will work closely with industry to deliver tangible progress within a set timeframe.
To ask His Majesty's Government what assessment they have made of whether the Voluntary Scheme for Branded Medicines Pricing and Access has caused a reduction in the supply of biosimilar medicines, and any associated impact on (1) patient outcomes, (2) NHS finances in the short term, and (3) the ability...
To ask His Majesty's Government what assessment they have made of whether the Voluntary Scheme for Branded Medicines Pricing and Access has caused a reduction in the supply of biosimilar medicines, and any associated impact on (1) patient outcomes, (2) NHS finances in the short term, and (3) the ability...
The Department recognises the important role that biosimilars and generics play in ensuring affordability, patient access, and supply resilience. We have not seen convincing evidence that the voluntary scheme for branded medicines pricing and access has had an impact on medicines supply including biosimilars, given available mitigations such as provisions in the scheme for companies to apply for price increases should supply of products be otherwise uneconomical.
To ask His Majesty's Government what volume of sales under the Voluntary Scheme for Branded Medicines Pricing and Access are off-patent medicines; and how the suppliers of such medicines are represented in negotiations for the next scheme.
To ask His Majesty's Government what volume of sales under the Voluntary Scheme for Branded Medicines Pricing and Access are off-patent medicines; and how the suppliers of such medicines are represented in negotiations for the next scheme.
The information requested is not held centrally. It would not be appropriate for us to comment on a representation of the off-patent sector as this is closely connected with an ongoing legal case.
Lords motion to regret. Motion withdrawn.
Lords motion to regret. Motion withdrawn.
As I said, this is about the scheme and the pricing for this year. The negotiations happening now are about future years, while, technically, this debate is about making sure that the alignment is there for this year and its pricing. Given that the discount has been decided on for...
As I said, this is about the scheme and the pricing for this year. The negotiations happening now are about future years, while, technically, this debate is about making sure that the alignment is there for this year and its pricing. Given that the discount has been decided on for...
My Lords, I am very glad to introduce this debate, and thankful to noble Lords who have stayed to take part in it. Underpinning this debate is a major concern about the current state of the UK economy, beset as it is with low growth, low productivity, workforce shortages, regional...
My Lords, I am very glad to introduce this debate, and thankful to noble Lords who have stayed to take part in it. Underpinning this debate is a major concern about the current state of the UK economy, beset as it is with low growth, low productivity, workforce shortages, regional...
My Lords, I intervene in this short debate just to make a number of points that I feel strongly about and have done for quite a long time, because now is an important moment, when the Government are entering the process of negotiating the voluntary price access scheme starting at...
My Lords, I intervene in this short debate just to make a number of points that I feel strongly about and have done for quite a long time, because now is an important moment, when the Government are entering the process of negotiating the voluntary price access scheme starting at...
My Lords, I support the regret Motion moved so ably by the noble Lord, Lord Hunt of Kings Heath. I agree with quite a lot of what the noble Lord, Lord Lansley, has said, but I am not going to be as wide-ranging as him. The Minister may be relieved...
My Lords, I support the regret Motion moved so ably by the noble Lord, Lord Hunt of Kings Heath. I agree with quite a lot of what the noble Lord, Lord Lansley, has said, but I am not going to be as wide-ranging as him. The Minister may be relieved...
My Lords, I am very grateful to the noble Lord, Lord Hunt, for his Motion, and for giving us an opportunity to debate a series of questions raised by the statutory instrument about the life sciences sector more broadly.
I do not think that it is enough for us simply to...
My Lords, I am very grateful to the noble Lord, Lord Hunt, for his Motion, and for giving us an opportunity to debate a series of questions raised by the statutory instrument about the life sciences sector more broadly.
I do not think that it is enough for us simply to...
My Lords, I thank my noble friend for his usual expert and comprehensive explanation of his regret Motion on this SI, which is so important for the future of the NHS and the UK’s pharmaceutical industry and life sciences sector.
While the Government’s argument for maintaining equivalence between the two schemes...
My Lords, I thank my noble friend for his usual expert and comprehensive explanation of his regret Motion on this SI, which is so important for the future of the NHS and the UK’s pharmaceutical industry and life sciences sector.
While the Government’s argument for maintaining equivalence between the two schemes...
I thank noble Lords for the debate, and I particularly thank the noble Lord, Lord Hunt, for bringing forward this important subject. It was clear from the contributions of noble Lords that we all want the same thing here, and this is a discussion about how best to achieve it....
I thank noble Lords for the debate, and I particularly thank the noble Lord, Lord Hunt, for bringing forward this important subject. It was clear from the contributions of noble Lords that we all want the same thing here, and this is a discussion about how best to achieve it....
I am sorry to interrupt the Minister’s flow. He said that we are having the fruitful discussions that the Prime Minister wants with the industry and that they are starting to progress. However, the industry itself is starting with a figure in the single figures, nowhere near 27%. I am...
I am sorry to interrupt the Minister’s flow. He said that we are having the fruitful discussions that the Prime Minister wants with the industry and that they are starting to progress. However, the industry itself is starting with a figure in the single figures, nowhere near 27%. I am...
The mechanics behind this debate—I was planning to say that my noble friend Lord Lansley made this point—are about the alignment of the voluntary and statutory schemes. I think that we would all agree that it is sensible that the two are roughly aligned. We can argue over how high...
The mechanics behind this debate—I was planning to say that my noble friend Lord Lansley made this point—are about the alignment of the voluntary and statutory schemes. I think that we would all agree that it is sensible that the two are roughly aligned. We can argue over how high...
I am sorry to interrupt the Minister again. We are talking about signals given to the outside world, in these discussions that are now taking place about the voluntary scheme. As the noble Lord, Lord Lansley, asked, rather elegantly, why do we have two schemes in the first place? There...
I am sorry to interrupt the Minister again. We are talking about signals given to the outside world, in these discussions that are now taking place about the voluntary scheme. As the noble Lord, Lord Lansley, asked, rather elegantly, why do we have two schemes in the first place? There...
My Lords, I am very grateful to the Minister. I think he has responded in a positive way, which is gratifying and, I hope, sets the foundation for a proper negotiation with the industry to get a jointly owned voluntary scheme which will incentivise global pharma to invest in the...
My Lords, I am very grateful to the Minister. I think he has responded in a positive way, which is gratifying and, I hope, sets the foundation for a proper negotiation with the industry to get a jointly owned voluntary scheme which will incentivise global pharma to invest in the...
May I just clarify? I completely agree that medicines are of course valuable. My comments were not about not spending money on medicines but about getting value for what we spend on medicines—not the quantity, not the quality, but the price that we are paying. I think that all noble...
May I just clarify? I completely agree that medicines are of course valuable. My comments were not about not spending money on medicines but about getting value for what we spend on medicines—not the quantity, not the quality, but the price that we are paying. I think that all noble...